Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx

Trial Profile

Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Docetaxel
  • Indications Hypopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2012 Actual initiation date changed from 1 Feb 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual initiation date changed from 1 Aug 2011 to February 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top